Cargando…

Vaccination against type 1 angiotensin receptor prevents streptozotocin-induced diabetic nephropathy

ABSTRACT: Recently, our group has developed a therapeutic hypertensive vaccine against angiotensin (Ang) II type 1 receptor (AT1R) named ATRQβ-001. To explore its potential effectiveness on streptozotocin-induced diabetic nephropathy, male Sprague Dawley rats were randomly divided into two groups: a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Dan, Du, Yimei, Qiu, Zhihua, Yan, Sen, Chen, Fen, Wang, Min, Yang, Shijun, Zhou, Yanzhao, Hu, Xiajun, Deng, Yihuan, Wang, Shijia, Wang, Liangping, Zhang, Hongrong, Wu, Hailang, Yu, Xian, Zhou, Zihua, Liao, Yuhua, Chen, Xiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4762923/
https://www.ncbi.nlm.nih.gov/pubmed/26407577
http://dx.doi.org/10.1007/s00109-015-1343-6
_version_ 1782417165052280832
author Ding, Dan
Du, Yimei
Qiu, Zhihua
Yan, Sen
Chen, Fen
Wang, Min
Yang, Shijun
Zhou, Yanzhao
Hu, Xiajun
Deng, Yihuan
Wang, Shijia
Wang, Liangping
Zhang, Hongrong
Wu, Hailang
Yu, Xian
Zhou, Zihua
Liao, Yuhua
Chen, Xiao
author_facet Ding, Dan
Du, Yimei
Qiu, Zhihua
Yan, Sen
Chen, Fen
Wang, Min
Yang, Shijun
Zhou, Yanzhao
Hu, Xiajun
Deng, Yihuan
Wang, Shijia
Wang, Liangping
Zhang, Hongrong
Wu, Hailang
Yu, Xian
Zhou, Zihua
Liao, Yuhua
Chen, Xiao
author_sort Ding, Dan
collection PubMed
description ABSTRACT: Recently, our group has developed a therapeutic hypertensive vaccine against angiotensin (Ang) II type 1 receptor (AT1R) named ATRQβ-001. To explore its potential effectiveness on streptozotocin-induced diabetic nephropathy, male Sprague Dawley rats were randomly divided into two groups: a control and a diabetic model. After 1 week, the diabetic rats were divided into four subgroups (each with 15 rats) for 14-week treatments with saline, olmesartan, ATRQβ-001, and Qβ virus-like particle (VLP), respectively. In addition to lower blood pressure, ATRQβ-001 vaccination ameliorated biochemical parameter changes of renal dysfunction, mesangial expansion, and fibrosis through inhibiting oxidative stress, macrophage infiltration, and proinflammatory factor expression. Furthermore, ATRQβ-001 vaccination suppressed renal Ang II-AT1R activation and abrogated the downregulation of angiotensin-converting enzyme 2-Ang (1–7), similar to olmesartan treatment, while no obvious feedback activation of circulating or local renin-angiotensin system (RAS) was only observed in vaccine group. In rat mesangial cells, the anti-ATR-001 antibody inhibited high glucose-induced transforming growth factor-β1 (TGF)-β1/Smad3 signal pathway. Additionally, no significant immune-mediated damage was detected in vaccinated animals. In conclusion, the ATRQβ-001 vaccine ameliorated streptozotocin-induced diabetic renal injury via modulating two RAS axes and inhibiting TGF-β1/Smad3 signal pathway, providing a novel, safe, and promising method to treat diabetic nephropathy. KEY MESSAGES: Overactivation of RAS plays a crucial role in the development of the DN. Our aim was to verify the effectiveness of ATRQβ-001 vaccine in STZ-induced DN. The ATRQβ-001 modulated two RAS axes and inhibited TGF-β1/Smad3 signal pathway. The vaccine therapy may provide a novel, safe, and promising method to treat DN. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00109-015-1343-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4762923
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-47629232016-03-03 Vaccination against type 1 angiotensin receptor prevents streptozotocin-induced diabetic nephropathy Ding, Dan Du, Yimei Qiu, Zhihua Yan, Sen Chen, Fen Wang, Min Yang, Shijun Zhou, Yanzhao Hu, Xiajun Deng, Yihuan Wang, Shijia Wang, Liangping Zhang, Hongrong Wu, Hailang Yu, Xian Zhou, Zihua Liao, Yuhua Chen, Xiao J Mol Med (Berl) Original Article ABSTRACT: Recently, our group has developed a therapeutic hypertensive vaccine against angiotensin (Ang) II type 1 receptor (AT1R) named ATRQβ-001. To explore its potential effectiveness on streptozotocin-induced diabetic nephropathy, male Sprague Dawley rats were randomly divided into two groups: a control and a diabetic model. After 1 week, the diabetic rats were divided into four subgroups (each with 15 rats) for 14-week treatments with saline, olmesartan, ATRQβ-001, and Qβ virus-like particle (VLP), respectively. In addition to lower blood pressure, ATRQβ-001 vaccination ameliorated biochemical parameter changes of renal dysfunction, mesangial expansion, and fibrosis through inhibiting oxidative stress, macrophage infiltration, and proinflammatory factor expression. Furthermore, ATRQβ-001 vaccination suppressed renal Ang II-AT1R activation and abrogated the downregulation of angiotensin-converting enzyme 2-Ang (1–7), similar to olmesartan treatment, while no obvious feedback activation of circulating or local renin-angiotensin system (RAS) was only observed in vaccine group. In rat mesangial cells, the anti-ATR-001 antibody inhibited high glucose-induced transforming growth factor-β1 (TGF)-β1/Smad3 signal pathway. Additionally, no significant immune-mediated damage was detected in vaccinated animals. In conclusion, the ATRQβ-001 vaccine ameliorated streptozotocin-induced diabetic renal injury via modulating two RAS axes and inhibiting TGF-β1/Smad3 signal pathway, providing a novel, safe, and promising method to treat diabetic nephropathy. KEY MESSAGES: Overactivation of RAS plays a crucial role in the development of the DN. Our aim was to verify the effectiveness of ATRQβ-001 vaccine in STZ-induced DN. The ATRQβ-001 modulated two RAS axes and inhibited TGF-β1/Smad3 signal pathway. The vaccine therapy may provide a novel, safe, and promising method to treat DN. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00109-015-1343-6) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2015-09-26 2016 /pmc/articles/PMC4762923/ /pubmed/26407577 http://dx.doi.org/10.1007/s00109-015-1343-6 Text en © The Author(s) 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Ding, Dan
Du, Yimei
Qiu, Zhihua
Yan, Sen
Chen, Fen
Wang, Min
Yang, Shijun
Zhou, Yanzhao
Hu, Xiajun
Deng, Yihuan
Wang, Shijia
Wang, Liangping
Zhang, Hongrong
Wu, Hailang
Yu, Xian
Zhou, Zihua
Liao, Yuhua
Chen, Xiao
Vaccination against type 1 angiotensin receptor prevents streptozotocin-induced diabetic nephropathy
title Vaccination against type 1 angiotensin receptor prevents streptozotocin-induced diabetic nephropathy
title_full Vaccination against type 1 angiotensin receptor prevents streptozotocin-induced diabetic nephropathy
title_fullStr Vaccination against type 1 angiotensin receptor prevents streptozotocin-induced diabetic nephropathy
title_full_unstemmed Vaccination against type 1 angiotensin receptor prevents streptozotocin-induced diabetic nephropathy
title_short Vaccination against type 1 angiotensin receptor prevents streptozotocin-induced diabetic nephropathy
title_sort vaccination against type 1 angiotensin receptor prevents streptozotocin-induced diabetic nephropathy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4762923/
https://www.ncbi.nlm.nih.gov/pubmed/26407577
http://dx.doi.org/10.1007/s00109-015-1343-6
work_keys_str_mv AT dingdan vaccinationagainsttype1angiotensinreceptorpreventsstreptozotocininduceddiabeticnephropathy
AT duyimei vaccinationagainsttype1angiotensinreceptorpreventsstreptozotocininduceddiabeticnephropathy
AT qiuzhihua vaccinationagainsttype1angiotensinreceptorpreventsstreptozotocininduceddiabeticnephropathy
AT yansen vaccinationagainsttype1angiotensinreceptorpreventsstreptozotocininduceddiabeticnephropathy
AT chenfen vaccinationagainsttype1angiotensinreceptorpreventsstreptozotocininduceddiabeticnephropathy
AT wangmin vaccinationagainsttype1angiotensinreceptorpreventsstreptozotocininduceddiabeticnephropathy
AT yangshijun vaccinationagainsttype1angiotensinreceptorpreventsstreptozotocininduceddiabeticnephropathy
AT zhouyanzhao vaccinationagainsttype1angiotensinreceptorpreventsstreptozotocininduceddiabeticnephropathy
AT huxiajun vaccinationagainsttype1angiotensinreceptorpreventsstreptozotocininduceddiabeticnephropathy
AT dengyihuan vaccinationagainsttype1angiotensinreceptorpreventsstreptozotocininduceddiabeticnephropathy
AT wangshijia vaccinationagainsttype1angiotensinreceptorpreventsstreptozotocininduceddiabeticnephropathy
AT wangliangping vaccinationagainsttype1angiotensinreceptorpreventsstreptozotocininduceddiabeticnephropathy
AT zhanghongrong vaccinationagainsttype1angiotensinreceptorpreventsstreptozotocininduceddiabeticnephropathy
AT wuhailang vaccinationagainsttype1angiotensinreceptorpreventsstreptozotocininduceddiabeticnephropathy
AT yuxian vaccinationagainsttype1angiotensinreceptorpreventsstreptozotocininduceddiabeticnephropathy
AT zhouzihua vaccinationagainsttype1angiotensinreceptorpreventsstreptozotocininduceddiabeticnephropathy
AT liaoyuhua vaccinationagainsttype1angiotensinreceptorpreventsstreptozotocininduceddiabeticnephropathy
AT chenxiao vaccinationagainsttype1angiotensinreceptorpreventsstreptozotocininduceddiabeticnephropathy